A pharmacokinetic and pharmacogenetic study of efavirenz in children: Dosing guidelines can result in subtherapeutic concentrations

Antiviral Therapy

Volumn 13, Issue 6, 2008, Pages 779-787

  ter Heine, Rob ^a   Scherpbier, Henriette J ^b   Crommentuyn, Kristel M L ^a   Bekker, Vincent ^b   Beijnen, Jos H ^a   Kuijpers, Taco W ^b   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2B6; DIDANOSINE; EFAVIRENZ; GUANINE; LAMIVUDINE; LIVER ENZYME; THYMINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLOMETRY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; NETHERLANDS; NONLINEAR SYSTEM; PEDIATRIC HOSPITAL; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; SEX DIFFERENCE; SIDE EFFECT; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PRACTICE GUIDELINES AS TOPIC;

EID: 53149086277     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007; 119:e705-e715.
2. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit 2006; 28:468-473.
3. Brundage R, Fletcher CV, Fiske WD, et al. Pharmacokinetics of an efavirenz suspension in children. 6th Conference on Retroviruses and Opportunistic Infections. 31 January - 4 February 1999, Chicago, IL, USA. Abstract 424.
4. Joshi AS, Barrett JS, Fiske WD, Pieniaszek HJLTM, Bacheler IT, Saitoh A. Population pharmacokinetics of efavirenz in Phase II studies and relationship with efficacy. 39th Interscience Conference Antimicrobial Agents and Chemothrapy. 26-29 September 1999, San Francisco, CA, USA. Abstract 1201.
5. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
6. Fletcher CV, Brundage RC, Fenton T, et al. Pharmacokinetics and Pharmacodynamics of efavirenz; and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther 2007; 83:300-306.
7. Ren Y, Nuttall JJ, Egbers C, et al. High prevalence of subtherapeutic plasma concentrations ot efavirenz in children. J Acquir Immune Defic Syndr 2007; 45:133-136.
8. von Hentig N, Koenigs C, Elanjikal S, et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. Eur J Med Res 2006; 11:377-380.
9. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-2400.
10. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenz pharmacokinetics; in HIV-1-infected children are associated with CYP2B6-GS16T polymorphism. J Acquir Immune Defic Syndr 2007; 45:280-285.
11. Hofmann MH, Blievernicht JK, Klein K, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-292.
12. European Medicines Agency website 2008. Scientific discussion for the approval of Stocrin. (Updated 3 January 2004. Accessed8 August 2008.) Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/Stocrin/ 127599en6.pdf
13. Kappelhoff BS, Rosing H, Huitema AD, Beijnen JH. Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. J Chromatogr B Analyt Tecbnol Biomed Life Sci 2003; 792:353-362.
14. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
15. Beal SL, Sheiner LB. NONMEM User's Guides 1998. NONMEM project group, University of California, San Francisco, CA, USA.
16. Jonsson EN, Karisson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58:51-64.
17. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-a Perl module or NONMEM related programming. Comput Methods Programs Biomed 2004; 75:85-94.
18. Hooker AC, Staatz CE, Karisson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24:2187-2197.
19. Keizer RJ. Piraña 0.99beta 2008. (Updated 29 July 2008. Accessed 8 August 2008.) Available from http://sourceforge.net/projects/pirana/
20. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165:819-829.
21. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165:741-746.
22. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2007; 48:303-332.
23. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44:849-861.
24. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21:735-750.
25. Zandvliet AS, Huitema AD, Copalu W, et al. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res 2007; 13:2970-2976.
26. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73:20-30.
27. Kappelhoff BS, van LF, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155.
28. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G→>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64:357-365.
29. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HTV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
30. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-1237.